Nilotinib (CAS 641571-10-0) – Anticancer API

Nilotinib (CAS 641571-10-0) is a high-potency anticancer API, belonging to the second-generation BCR-ABL tyrosine kinase inhibitor (TKI) class. Its unique molecular structure binds specifically to the ATP-binding site of BCR-ABL fusion protein, exerting stronger inhibitory activity than first-generation TKIs and overcoming most imatinib-resistant mutations. Produced via advanced precision synthesis, it maintains ultra-high purity and consistent bioactivity, fully complying with international pharmaceutical quality standards.

This premium API is a core raw material for pharmaceutical manufacturers developing targeted leukemia therapies. It is widely applied in formulating drugs for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), suitable for newly diagnosed patients and those with imatinib resistance or intolerance. With proven clinical efficacy in improving molecular response rates and prolonging survival, it addresses the critical need for effective CML treatments. For pharmaceutical R&D teams and production enterprises, it provides a trusted, high-performance solution to advance precision oncology therapy.